Nycomed Annual Report 2008 - Takeda Pharmaceuticals ...

Nycomed Annual Report 2008 21severity of these attacks can have a highlydeleterious effect on the patient’s moraleand quality of life. Sufferers need somethingthat will give immediate relief. Instanyl ® isan intranasally applied Fentanyl spray thathas been developed in-house by Nycomed.It is intended for managing breakthroughpain in adult cancer patients.Nasal Fentanyl has a profile that will providepatients with a rapid onset of action andadequately short duration, closely matchingthe typical breakthrough pain episode.Instanyl ® was filed for EU approval inDecember 2007. Nycomed plans to launchInstanyl ® during the second half of 2009.Two in-licensing examplesOptesia ®At present, there is no standard regimenfor post-operative pain treatment. Painmanagement is generally achieved with acombination of different drugs, such as nonsteroidalanti-inflammatory drugs (NSAIDs),paracetamol, opioids and short-acting localanaesthetics (wound infiltration and nerveblocks). However, NSAIDs on their own areoften inadequate analgesics for moderateand severe pain, while opioids can causeserious side effects and local anaestheticsonly last for a few hours.Optesia ® (Saber-bupivacaine) addressesthis unmet medical need for long-termpost-operative pain relief in a number ofsurgical procedures. Bupivacaine blockssensory nerve impulse conduction to thebrain’s cortex and is slowly released fromthe administered drug to provide longlastingpain relief.Optesia ® is in-licensed from Durect Corp.and is currently in phase II clinical development.Nycomed has the commercial rightsfor Europe, Russia, CIS, Australia and anumber of Latin American countries.VeltuzumabNycomed and Immunomedics are collaboratingon Veltuzumab, a humanised anti-CD20antibody that is currently undergoing clinicaltrials in cancer and autoimmune diseases.Anti-CD20 antibodies target B-cells, whichplay an important role in the productionof autoantibodies and are the major causeof various autoimmune diseases, includingrheumatoid arthritis (RA).Nycomed is developing Veltuzumab forrheumatoid arthritis as the primary indication.Under the agreement with Immunomedics, wehave exclusive, worldwide rights to develop,manufacture and commercialise the subcutaneousformulation of Veltuzumab for thetreatment of all non-cancer indications.Veltuzumab is currently in phase II clinical trials.Clinical development pipeline features promising projectsPhase I Phase II Phase III RegistrationRoflumilast dermalAtopic dermatitis/ psoriasisOptesia ®Incision-related painPartner: DurectImagify ®Cardiovascular imagingPartner: AcusphereInstanyl ®Breakthrough painPDE4 inhibitorInflammationVeltuzumabRheumatoid arthritisPartner: ImmunomedicsTeduglutideShort bowel syndromePartner: NPSDaxas ® , COPDPartner Japan: MitsubishiTanabe PharmaCiclesonide HFA nasalAllergic rhinitisPartner: SepracorAlendronate effervescentOsteoporosisPartner: EffRxOur pipeline is built from our own research and through co-developments with partners. Co-development with partners